These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38382235)

  • 1. 'Financial fallout' in the US biopharmaceutical industry: Maximizing shareholder value, regulatory capture, and the consequences for patients.
    Whitacre R
    Soc Sci Med; 2024 Mar; 344():116598. PubMed ID: 38382235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are our medicines so expensive? Spoiler: Not for the reasons you are being told….
    Torreele E
    Eur J Gen Pract; 2024 Dec; 30(1):2308006. PubMed ID: 38299574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of financial statements from companies in the Brazilian health sector (2009-2015): concentration, centralization of capital, and expressions of financialization].
    Andrietta LS; Monte-Cardoso A
    Cad Saude Publica; 2022; 38Suppl 2(Suppl 2):e00006020. PubMed ID: 36043616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From community pharmacies to big pharmacy chains: private provision of medicines, health system, and financialization of the Brazilian retail pharmacy market].
    Mattos LV; Silva RMD; Silva FDRPD; Luiza VL
    Cad Saude Publica; 2022; 38Suppl 2(Suppl 2):e00085420. PubMed ID: 36043623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow.
    Jakovljevic M; Wu W; Merrick J; Cerda A; Varjacic M; Sugahara T
    J Med Econ; 2021 Nov; 24(sup1):42-50. PubMed ID: 34915798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
    Coghlan R; Stephens P; Mwale B; Siyanga M
    Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Financialization of Heavily Polluting Enterprises on Technological Innovation under the Background of Environmental Pollution Control.
    Zhou Y; Du Y; Lei F; Su Z; Feng Y; Li J
    Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the purpose of ultra-processed food? An exploratory analysis of the financialisation of ultra-processed food corporations and implications for public health.
    Wood B; Robinson E; Baker P; Paraje G; Mialon M; van Tulleken C; Sacks G
    Global Health; 2023 Nov; 19(1):85. PubMed ID: 37957671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study.
    Meyers DE; Meyers BS; Chisamore TM; Wright K; Gyawali B; Prasad V; Sullivan R; Booth CM
    Cancer; 2022 Jan; 128(2):311-316. PubMed ID: 34614198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corporate financialization, financing constraints, and innovation efficiency-Empirical evidence based on listed Chinese pharmaceutical companies.
    Zhu J; Tang Y; Wei Y; Wang S; Chen Y
    Front Public Health; 2023; 11():1085148. PubMed ID: 37124778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries.
    Popa C; Holvoet K; Van Montfort T; Groeneveld F; Simoens S
    Front Pharmacol; 2018; 9():1108. PubMed ID: 30327601
    [No Abstract]   [Full Text] [Related]  

  • 18. How High-Polluting Firms Suffer from Being Distracted form Intended Purpose: A Corporate Social Responsibility Perspective.
    Zhao XZ; Chen J; Chen FW; Wang W; Xia S
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33317027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 20. Why do sports goods manufacturers choose different corporate social responsibility engagements?
    Guo Y; Kang D; Huang C; Chen Y
    PLoS One; 2023; 18(12):e0295682. PubMed ID: 38128059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.